NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
Investigated for use/treatment in alzheimer's disease and schizophrenia and schizoaffective disorders.
No associated conditions information available.
Stay informed with timely notifications on clinical trials and research advancements.